Is Arena Pharmaceuticals, Inc. (ARNA) Stock About to Get Hot Tuesday?

Tuesday, March 08, 2022 10:33 AM | InvestorsObserver Analysts

Mentioned in this article

Is Arena Pharmaceuticals, Inc. (ARNA) Stock About to Get Hot Tuesday?

Overall market sentiment has been down on Arena Pharmaceuticals, Inc. (ARNA) stock lately. ARNA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Arena Pharmaceuticals, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ARNA!

See Full ARNA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ARNA Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock has risen 5.3% while the S&P 500 is lower by -0.42% as of 10:31 AM on Tuesday, Mar 8. ARNA has risen $4.96 from the previous closing price of $93.62 on volume of 1,385,385 shares. Over the past year the S&P 500 is up 9.48% while ARNA has risen 37.95%. ARNA lost -$10.14 per share in the over the last 12 months. To screen for more stocks like Arena Pharmaceuticals, Inc. click here.

More About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.